Michael Dunn Reflects on all ASH25 Represents for the Bleeding Disorders Community
Michael Dunn, Vice President – Head of Rare Disease Portfolio at Genentech, shared on LinkedIn:
”I’m pausing to take a moment to reflect on all ASH25 represents for the bleeding disorders community – innovation, hope, progress.
I feel energized to be here.
Connecting with brilliant minds, learning about the latest advancements in hematology, and sharing how Genentech is advancing the standard of care for patients and their families.
I’m proud to be part of an organization that prioritizes standing alongside the hemophilia A community.
Every step forward is driven by our commitment to push the boundaries of what’s possible and deliver meaningful progress for people living with bleeding disorders.
A big thank you to the local Florida team for their above and beyond efforts at the booth Jeremy V., Lucila Ramirez Donaldson, William Lopez and to members of the leadership team who were representing our collective efforts for those with bleeding disorders Erik Lundgren, Tony Lin, Juliana Lagrasta Biondo, Gina Noh”
All from ASH25 featured in Hemostasis Today.
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria